Iterative Health, a healthcare technology and services company advancing GI clinical research, and One GI, a top physician-led management services organization (MSO) and portfolio company of Webster Equity Partners, announced a strategic partnership to advance clinical research as a core ancillary service for OneGI’s community providers, while expanding access to innovative trials. The collaboration reinforces research as an integral offering in community-based gastroenterology (GI) care across a leading network of independent physician practices.
Health Technology Insights: Acorn Health Names Mony Iyer CEO
“Advancing medicine through research is central to our mission of improving health outcomes for our patients and communities,” said Christa Newton, CEO of One GI. “Our partnership with Iterative Health strengthens our established research ancillary through shared expertise and proven support, ensuring our physicians can expand patients’ access to leading-edge treatments.”
One GI’s network includes 34 clinics across six states, providing excellence in gastroenterology care through a physician-led model. Its research ancillary, comprised of 13 active sites, is now an exclusive mainstay in Iterative Health’s global site network. This collaboration brings together One GI’s strong research capabilities and Iterative Health’s proven site-serving operational model, building on a history of delivering high-quality trials at scale with unmatched speed and performance.
Health Technology Insights: Quanterix Accelerator Lab Earns New York Clinical Lab Permit
“Iterative Health has been a trusted partner to our site for several years, and I’ve seen firsthand the depth of their support and expertise,” said Dr. Ziad Younes, a global leader in gastroenterology and principal investigator at One GI. “By enhancing our research operations, they’ve allowed my team to focus fully on what matters most—caring for our patients. This new partnership ensures even more One GI physicians can offer cutting-edge therapies close to home, without patients ever needing to leave the communities and providers they know and trust.”
“We are privileged that One GI has chosen to partner with Iterative Health in our journey to create the highest quality and fastest network of Gastroenterology research sites,” said Jonathan Ng, CEO of Iterative Health. “In partnership with One GI research, we have consistently demonstrated industry-leading results through our unique operating model over the past two years. We look forward to furthering clinical trial innovation together in the years ahead.”
Health Technology Insights: DAWNZERA Approved as First RNA Prophylactic Hereditary Angioedema Treatment
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
